Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials

Meta-Analysis to Assess the Quality of International Normalized Ratio Control and Associated Outcomes in Venous Thromboembolism Patients

(2014) Elizabeth S. Mearns et al.   THROMBOSIS RESEARCH

Antithrombotic Therapy for VTE Disease

(2012) Clive Kearon et al.   CHEST

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial

(2011) Drahomir Aujesky et al.   LANCET

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial

(2011) Harry R Büller et al.   LANCET

Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism

(2010) M. J. KOVACS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis

(2010) T. BAGLIN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis

(2010)   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

A Randomised Open-Label Trial Comparing Long-term Sub-Cutaneous Low-Molecular-weight Heparin Compared with Oral-Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis

(2009) A. Romera et al.   EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY

Patient Outcomes After Deep Vein Thrombosis and Pulmonary EmbolismThe Worcester Venous Thromboembolism Study

(2008) Frederick A. Spencer   ARCHIVES OF INTERNAL MEDICINE

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study

(2008) H. R. Buller et al.   BLOOD

Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

(2008) et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS